Enterologics, Inc. was founded for the sole purpose of making probiotics available as new therapeutic alternatives for inadequately treated gastrointestinal diseases. The company operates as a virtual team of experts and partners with the best outside biologic production resources to keep development costs low and make time to market as fast as possible.
Probiotics are living bacteria or yeast that have a positive effect on the health of the individual consuming them. Many probiotics have been identified among the bacteria and yeasts that are used to ferment and preserve foods. Interest in probiotics in general has been growing, with Americans’ spending on probiotic supplements nearly tripling recently.
Enterologics is currently in the process of identifying unique probiotic strains that it will in-license or acquire. The team aims to build a strong scientific portfolio by extensive strain characterization, including state-of-the-art genomic profiling. Following development, the company will seek regulatory approval for these probiotic products for specific medical conditions.
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment